Want to see INSP full AI Analyst Report?
INSP Stock Chart & Stats
$61.07
$1.78(3.62%)
At close: 4:00 PM EDT
$61.07
$1.78(3.62%)
Day’s Range― - ―
52-Week Range$38.91 - $147.03
Previous CloseN/A
Volume140.99K
Average Volume (3M)656.96K
Market Cap
$2.11B
Enterprise Value$999.46
Total Cash (Recent Filing)$320.68M
Total Debt (Recent Filing)$29.09M
Price to Earnings (P/E)15.7
Beta0.95
Next Earnings
Nov 09, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.66
Shares Outstanding28,910,376
10 Day Avg. Volume645,876
30 Day Avg. Volume656,961
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$60.54Price Target Upside-0.87% Downside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)1.19
Revenue Forecast (FY)$853.86M
Bulls Say, Bears Say
Bulls Say
Low Leverage And LiquidityVery low leverage and a substantially expanded equity base give Inspire financial flexibility to fund commercial initiatives without relying heavily on borrowing. This strengthens resilience during reimbursement disruption and preserves capacity for investment, acquisitions, or other strategic priorities.
Improved Profitability And Cash GenerationThe company has moved from earlier losses to strong gross and net profitability while generating meaningful operating and free cash flow. This earnings profile can support continued investment in patient access, education, and therapy adoption while reinforcing business durability.
Clinical Evidence Supports AdoptionPositive clinical evidence strengthens the therapy’s value proposition for physicians, patients, and payors by linking Inspire V with meaningful outcomes. A stronger evidence base can support referral activity, physician adoption, and long-term expansion of the addressable treatment market.
Bears Say
Reimbursement Disruption Weighs On GrowthReimbursement and coding changes are directly disrupting demand conversion and revenue realization, creating a material obstacle to near-term growth. Continued uncertainty around WISeR and payment processes could delay procedures, complicate planning, and pressure results over coming quarters.
Near-term Margin And Earnings PressureLower revenue is creating unfavorable operating leverage at a time when marketing spending is expected to rise, pushing quarterly profitability toward breakeven. Persistently lower margins would reduce internal funding for growth and make earnings more sensitive to reimbursement recovery.
Cash Conversion Remains UnevenAlthough absolute cash generation is healthy, free cash flow has not consistently matched reported earnings and has fluctuated across periods. Uneven conversion can limit the predictability of internally funded investment and makes operating performance more dependent on working-capital and other cash-flow movements.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical Systems’s price range in the past 12 months?
Inspire Medical Systems lowest stock price was $38.91 and its highest was $147.03 in the past 12 months.
What is Inspire Medical Systems’s market cap?
Inspire Medical Systems’s market cap is $2.11B.
When is Inspire Medical Systems’s upcoming earnings report date?
Inspire Medical Systems’s upcoming earnings report date is Nov 09, 2026 which is in 56 days.
How were Inspire Medical Systems’s earnings last quarter?
Inspire Medical Systems released its earnings results on Aug 03, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.236 by $0.376.
Is Inspire Medical Systems overvalued?
According to Wall Street analysts Inspire Medical Systems’s price is currently Overvalued.
Does Inspire Medical Systems pay dividends?
Inspire Medical Systems does not currently pay dividends.
What is Inspire Medical Systems’s EPS estimate?
Inspire Medical Systems’s EPS estimate is 0.08.
How many shares outstanding does Inspire Medical Systems have?
Inspire Medical Systems has 28,910,376 shares outstanding.
What happened to Inspire Medical Systems’s price movement after its last earnings report?
Inspire Medical Systems reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.236. Following the earnings report the stock price went up 22.827%.
Which hedge fund is a major shareholder of Inspire Medical Systems?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$60.54 (-0.87% Downside)
$60.54 (-0.87% Downside)
Blogger Sentiment
Bullish
INSP Sentiment 90%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inspire Medical Systems
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
INSP Company Deck
INSP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: meaningful near-term headwinds from coding and reimbursement disruption depressed top-line growth (Q2 revenue down 7.6% and a full-year disruption impact estimated at $120M–$130M), drove elevated tax and restructuring items, and widened near-term guidance. Offsetting these challenges, management delivered profitability and positive operating cash flow ahead of expectations, possesses a strong cash position ($415M, no debt), announced Project Horizon to create $30M of reinvestment capacity, and highlighted strong clinical evidence and favorable proposed CMS facility reimbursement changes (+12% hospital, +15% ASC for 2027). Given the comparable weight of material negatives (revenue/headwinds, restructuring, reimbursement uncertainty) and material positives (cashflow, balance sheet, clinical momentum and planned reinvestment), the overall tone is balanced with a path to recovery but meaningful near-term uncertainty.View all INSP earnings summariesINSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$60.54
▼(-0.87% Downside)
Technical Analysis
Ownership Overview
1.72% Insiders
28.63% Mutual Funds
27.36% Other Institutional Investors
14.28% Public Companies and
Individual Investors